XML 60 R68.htm IDEA: XBRL DOCUMENT v3.20.1
Debt Agreements - Term Loan Facility and Revolving Credit Facility - Additional Information (Detail) - USD ($)
1 Months Ended 3 Months Ended
Dec. 18, 2019
Mar. 18, 2019
Mar. 11, 2019
Jul. 31, 2019
Mar. 31, 2019
Jun. 30, 2018
Mar. 31, 2020
Dec. 31, 2019
Jul. 16, 2019
Debt Instrument [Line Items]                  
Outstanding principal amount             $ 1,418,026,000 $ 1,418,026,000 $ 625,000,000.0
2019 Term Loan Facility [Member]                  
Debt Instrument [Line Items]                  
LIBOR floor rate 0.00%                
Interest rate description             The December 2019 Refinancing Loans were incurred as a separate new class of term loans under the Credit Agreement with substantially the same terms as the previously outstanding senior secured term loans incurred on May 22, 2019 (the “Refinanced Loans”) to effectuate a repricing of the Refinanced Loans.  The Borrower used the proceeds of the December 2019 Refinancing Loans to repay the Refinanced Loans, which totaled approximately $418.0 million.  The December 2019 Refinancing Loans bear interest at a rate, at the Borrower’s option, equal to the London Inter-Bank Offered Rate (“LIBOR”), plus 2.25% per annum (subject to a 0.00% LIBOR floor) or the adjusted base rate plus 1.25% per annum, with a step-down to LIBOR plus 2.00% per annum or the adjusted base rate plus 1.00% per annum at the time the Company’s leverage ratio is less than or equal to 2.00 to 1.00.  The adjusted base rate is defined as the greatest of (a) LIBOR (using one-month interest period) plus 1.00%, (b) the prime rate, (c) the federal funds rate plus 0.50%, and (d) 1.00%.      
Proceeds from debt issuances, percentage on excess cash flow 50.00%                
Premium on repayment of debt 1.00%                
Proceeds from debt issuances, reduction percentage on excess cash flow 25.00%                
Proceeds from debt issuances, percentage on first lien leverage ratio 0.00%                
Credit agreement, description             The Borrower is permitted to make voluntary prepayments of the loans under the Credit Agreement at any time without payment of a premium, except that with respect to the December 2019 Refinancing Loans, a 1% premium will apply to a repayment of the December 2019 Refinancing Loans in connection with a repricing of, or any amendment to the Credit Agreement in a repricing of, such loans effected on or prior to the date that is six months following December 18, 2019.  The Borrower is required to make mandatory prepayments of loans under the Credit Agreement (without payment of a premium) with (a) net cash proceeds from certain non-ordinary course asset sales (subject to reinvestment rights and other exceptions), (b) casualty proceeds and condemnation awards (subject to reinvestment rights and other exceptions), (c) net cash proceeds from issuances of debt (other than certain permitted debt), and (d) 50% of the Company’s excess cash flow (subject to decrease to 25% or 0% if the Company’s first lien leverage ratio is less than 2.25:1 or 1.75:1, respectively).  The principal amount of the December 2019 Refinancing Loans are due and payable on May 22, 2026, the final maturity date of the December 2019 Refinancing Loans.      
Maturity date of debt instrument May 22, 2026                
2019 Term Loan Facility [Member] | Horizon Pharma Subsidiaries [Member]                  
Debt Instrument [Line Items]                  
Cut off percentage for defining limited liability subsidiaries, portion of capital stock held maximum 65.00%                
2019 Term Loan Facility [Member] | Minimum [Member]                  
Debt Instrument [Line Items]                  
Debt instrument leverage ratio 2.00%                
Leverage ratio less than applicable margin 1.00%                
First lien leverage ratio 175.00%                
2019 Term Loan Facility [Member] | Maximum [Member]                  
Debt Instrument [Line Items]                  
Debt instrument leverage ratio 1.00%                
Leverage ratio less than applicable margin 2.00%                
First lien leverage ratio 225.00%                
2019 Term Loan Facility [Member] | Adjusted Base Rate [Member]                  
Debt Instrument [Line Items]                  
Debt instrument variable rate 1.25%                
2019 Term Loan Facility [Member] | Adjusted Base Rate [Member] | Step-down due to Leverage Ratio [Member]                  
Debt Instrument [Line Items]                  
Debt instrument variable rate 1.00%                
2019 Term Loan Facility [Member] | London Interbank Offered Rate (LIBOR) [Member]                  
Debt Instrument [Line Items]                  
Debt instrument variable rate 2.25%                
2019 Term Loan Facility [Member] | London Interbank Offered Rate (LIBOR) [Member] | Step-down due to Leverage Ratio [Member]                  
Debt Instrument [Line Items]                  
Debt instrument variable rate 2.00%                
Refinancing Loans [Member]                  
Debt Instrument [Line Items]                  
Repayment of refinanced loans, amount $ 418,000,000.0                
Revolving Credit Facility [Member]                  
Debt Instrument [Line Items]                  
LIBOR floor rate 0.00%                
Interest rate description             The loans under the Revolving Credit Facility bear interest, at the Borrower’s option, at a rate equal to either LIBOR plus an applicable margin of 2.25% per annum (subject to a LIBOR floor of 0.00%), or the adjusted base rate plus 1.25% per annum, with a step-down to LIBOR plus 2.00% per annum or the adjusted base rate plus 1.00% per annum at the time the Company’s leverage ratio is less than or equal to 2.00 to 1.00.    
Minimum percentage of total commitments             25.00%    
Revolving Credit Facility [Member] | Adjusted Base Rate [Member]                  
Debt Instrument [Line Items]                  
Debt instrument variable rate 1.25%                
Revolving Credit Facility [Member] | Adjusted Base Rate [Member] | Step-down due to Leverage Ratio [Member]                  
Debt Instrument [Line Items]                  
Debt instrument variable rate 1.00%                
Revolving Credit Facility [Member] | London Interbank Offered Rate (LIBOR) [Member]                  
Debt Instrument [Line Items]                  
Debt instrument variable rate 2.25%                
Revolving Credit Facility [Member] | London Interbank Offered Rate (LIBOR) [Member] | Step-down due to Leverage Ratio [Member]                  
Debt Instrument [Line Items]                  
Debt instrument variable rate 2.00%                
Credit Agreement [Member]                  
Debt Instrument [Line Items]                  
Repaid under credit agreement           $ 23,500,000      
Credit Agreement [Member] | Mandatory Prepayment Provisions [Member]                  
Debt Instrument [Line Items]                  
Repaid under credit agreement         $ 35,000,000.0        
Credit Agreement [Member] | Term Loan Facility [Member]                  
Debt Instrument [Line Items]                  
Repaid under credit agreement   $ 300,000,000.0   $ 100,000,000.0          
Outstanding principal amount             $ 418,000,000.0    
Term Loan Facility [Member]                  
Debt Instrument [Line Items]                  
Debt instrument, variable interest rate             3.94%    
Debt instrument, effective interest rate             4.25%    
Horizon Pharma USA Inc [Member] | May 2019 Refinancing Loans [Member]                  
Debt Instrument [Line Items]                  
Line of credit facility borrowing capacity $ 418,000,000.0                
Horizon Pharma USA Inc [Member] | New Incremental Revolving Commitments [Member]                  
Debt Instrument [Line Items]                  
Aggregate principal amount     $ 200,000,000.0            
Line of credit facility additional borrowing capacity     $ 200,000,000.0            
Line of credit facility termination period     2024-03            
Horizon Pharma USA Inc [Member] | Letter of Credit Sub-facility [Member]                  
Debt Instrument [Line Items]                  
Line of credit facility additional borrowing capacity     $ 50,000,000.0            
Hyperion Therapeutics, Inc. [Member] | Term Loan Facility [Member] | 2018 Offering [Member]                  
Debt Instrument [Line Items]                  
Debt instrument, fair value             $ 390,900,000